Rakovina Therapeutics Inc

As of June 30, 2026, Rakovina Therapeutics Inc carries a market capitalization of 3.17M, placing it among publicly traded companies globally. Its enterprise value stands at 6.19M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Rakovina Therapeutics Inc's next confirmed earnings release is scheduled for November 26, 2026.

As of June 30, 2026, Rakovina Therapeutics Inc has 24.41M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Rakovina Therapeutics Inc maintains a current ratio of 0.15, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -147.56, indicating conservative leverage, while an interest coverage ratio of -12.00 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -140.30, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 10.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Rakovina Therapeutics Inc's stock has declined approximately 34.62% over the past 52 weeks. The 50-day moving average sits at 0.22, while the 200-day moving average is 0.15.

Over the twelve months ended June 30, 2026, Rakovina Therapeutics Inc generated - - in revenue and converted that into -7.08M in net income, yielding earnings per share of -0.32. EBITDA reached -6.05M, while operating income came in at -6.50M.

As of June 30, 2026, Rakovina Therapeutics Inc holds 200,115.00 in cash and equivalents against 3.22M in total debt, resulting in a net debt position of 3.02M. Total book value stands at -2.18M, with working capital of -2.13M providing operational flexibility.

Rakovina Therapeutics Inc produced -3.36M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -116.46: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -52.92, meaning Rakovina Therapeutics Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Rakovina Therapeutics Inc's most recent stock split took place on June 24, 2025 with a 10:1 split ratio.

As of June 30, 2026, Rakovina Therapeutics Inc has an Altman Z-Score of -167.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.